<DOC>
	<DOCNO>NCT00824668</DOCNO>
	<brief_summary>This trial conduct Europe . The aim clinical trial compare 24-hour pharmacodynamics/ pharmacokinetics biphasic insulin aspart 30 ( BiAsp 30 ) thrice daily treatment basal-bolus treatment insulin glargine insulin glulisine type 2 diabetic subject . Pharmacodynamics glucose-lowering effect study medication entire observation phase time administration efficacy period pharmacokinetics amount study insulin determine blood .</brief_summary>
	<brief_title>Comparison Pharmacodynamics Pharmacokinetics Biphasic Insulin Aspart 30 Insulin Glargine Insulin Glulisine Therapy Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Type 2 diabetes mellitus 12 month long Body Mass Index ( BMI ) : 25.040.0 kg/m2 , inclusive HbA1c 7.0 10.5 % screen Insulin treatment least 3 month prior screen total daily dose 0.6 0.9 U/kg body weight Use oral antidiabetic agent within past 2 month Cardiac disease : NYHA class III IV chronic heart failure ( CHF ) , unstable angina , and/or myocardial infarction ( treat untreated ) within 6 month prior screen Hepatic insufficiency ( alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) equal great 2 time central laboratory 's upper reference limit ) Renal insufficiency ( serum creatinine equal great 1.6 mg/dL male ; equal great 1.4 mg/dL female ) Recurrent hypoglycaemia Anaemia ( haemoglobin le 13.0 mg/dL male less 12.0 mg/dL female ; WHOcriteria ) Use concomitant medication ( prescribe nonprescribed insulin ) may alter glucose metabolism include limited : systemic inhaled glucocorticoid , anabolic steroid , nonselective betablockers</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>